ArticleInternational journal of clinical and experimental pathology2017
Clinical and prognostic significance of prokineticin 1 in human gliomas.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Therapeutic Potential of Targeting Prokineticin Receptors in Diseases.Pharmacological reviews · 2023Review
- Discovery of novel glioma serum biomarkers by proximity extension assay.Clinical proteomics · 2023Article
- Prokineticins as a Prognostic Biomarker for Low-Grade Gliomas: A Study Based on The Cancer Genome Atlas Data.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to explore the expression and the clinical and prognostic significance of prokineticin 1 (PROK1) in human gliomas. The expression of PROK1 in 60 patients with glioma and in eight control cases (patients with traumatic brain injury) by immunohistochemistry (IHC). The associations between the differences in expression and pathology grades were analyzed statistically. The positive rates of PROK1 expression in normal brain and glioma tissue were 25.0% (2/8) and 93.3% (56/60), respectively. PROK1 expression in glioma tissue was higher than that in normal tissue (
Indexed as
Identifiers
31966611PMC6965293W3026860444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.